Sweden's Getinge Q3 organic sales rise 2.1%

Getinge publ AB

21/10/2026 07:09

Overview
Swedish medtech supplier's Q3 organic net sales rose 2.1%, order intake up 2.6% yr/yr
Adjusted EBITA margin improved to 15.1%, supported by tariff refunds and currency effects
Free cash flow increased compared to the prior year

Outlook
Getinge maintains outlook for full-year 2026 organic net sales growth of 3–5%
Getinge says investment activity in pharma segment remains low, impacting Life Science outlook
Company cites uncertain global environment as a factor in maintaining its outlook

Result Drivers
ACUTE CARE THERAPIES - Co said sales growth was mainly driven by Acute Care Therapies, with Surgical Workflows providing stable order intake
LIFE SCIENCE MIXED - Strong performance reported in Sterile Transfer, while WIS products was impacted by low pharma investment
MARGIN GAINS - Co attributed margin improvement to favorable mix, price discipline and productivity improvements

Company press release: ID:nWkrv3B26

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Adjusted EPS
 
SEK 3.10
 
Q3 Adjusted EBITA
 
SEK 1.28 bln
 
Q3 Adjusted Gross Profit
 
SEK 4.34 bln
 
Q3 Free Cash Flow
 
SEK 1.30 bln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 6 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Getinge publ AB is SEK265.00, about 2% above its October 20 closing price of SEK259.70
The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 16 three months ago

Reuters Recommended Reads
Oct 21 - Sweden's Husqvarna slightly misses Q3 sales estimates amid weak demand
Oct 21 - Husqvarna to shift production from Europe to Asia as third quarter turns to loss
Oct 21 - Sweden's AddLife beats Q3 net sales expectations

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)